Skip to main content

Compare Stocks

Date Range: 

 COMPASS PathwaysRepare TherapeuticsDynavax TechnologiesOcular TherapeutixKronos Bio
SymbolNASDAQ:CMPSNASDAQ:RPTXNASDAQ:DVAXNASDAQ:OCULNASDAQ:KRON
Price Information
Current Price$34.39$32.38$7.80$14.81$24.80
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.51.61.71.61.7
Analysis Score3.52.53.53.53.5
Community Score3.83.92.53.04.2
Dividend Score0.00.00.00.00.0
Ownership Score0.00.81.70.80.0
Earnings & Valuation Score0.00.60.60.60.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$70.80$40.20$16.33$24.80$43.67
% Upside from Price Target105.87% upside24.15% upside109.40% upside67.45% upside76.08% upside
Trade Information
Market Cap$1.37 billion$1.20 billion$893.79 million$1.13 billion$1.39 billion
BetaN/AN/A1.342.29N/A
Average Volume430,150140,2635,086,3891,082,729180,839
Sales & Book Value
Annual RevenueN/AN/A$35.22 million$4.23 millionN/A
Price / SalesN/AN/A25.38267.11N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book ValueN/AN/A$0.10 per share($0.08) per shareN/A
Price / BookN/AN/A78.00-185.13N/A
Profitability
Net Income$-19,610,000.00N/A$-152,600,000.00$-86,370,000.00N/A
EPSN/AN/A($1.87)($2.01)N/A
Trailing P/E Ratio0.000.00N/AN/A0.00
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-256.92%-780.19%N/A
Return on Equity (ROE)N/AN/A-193.85%-14,065.71%N/A
Return on Assets (ROA)N/AN/A-23.45%-81.81%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A2.59%8.86%N/A
Current Ratio42.12%35.44%4.35%3.58%N/A
Quick Ratio42.11%35.44%3.47%3.53%N/A
Ownership Information
Institutional Ownership Percentage15.78%64.81%80.02%52.45%N/A
Insider Ownership PercentageN/AN/A13.33%7.70%N/A
Miscellaneous
Employees6110224518163
Shares Outstanding39.93 million36.98 million114.59 million76.29 million56.07 million
Next Earnings DateN/A8/12/2021 (Estimated)8/5/2021 (Estimated)8/6/2021 (Estimated)8/10/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableOptionableNot Optionable
SourceHeadline
Kronos Bio (NASDAQ:KRON) Sees Strong Trading VolumeKronos Bio (NASDAQ:KRON) Sees Strong Trading Volume
americanbankingnews.com - May 14 at 11:32 AM
Kronos Bio (NASDAQ:KRON) Trading Up 8.7%Kronos Bio (NASDAQ:KRON) Trading Up 8.7%
americanbankingnews.com - May 13 at 11:38 AM
Kronos Bio (NASDAQ:KRON) Issues Quarterly  Earnings ResultsKronos Bio (NASDAQ:KRON) Issues Quarterly Earnings Results
americanbankingnews.com - May 12 at 12:40 PM
Kronos Bio (NASDAQ:KRON) Shares Gap Up to $24.48Kronos Bio (NASDAQ:KRON) Shares Gap Up to $24.48
americanbankingnews.com - May 12 at 10:58 AM
Kronos Bio Reports Recent Business Progress and First Quarter Financial Results and Announces ...Kronos Bio Reports Recent Business Progress and First Quarter Financial Results and Announces ...
apnews.com - May 11 at 5:05 PM
Kronos Bio Reports Recent Business Progress and First Quarter Financial Results and Announces Virtual R&D DayKronos Bio Reports Recent Business Progress and First Quarter Financial Results and Announces Virtual R&D Day
finance.yahoo.com - May 11 at 5:05 PM
Kronos Bio (NASDAQ:KRON) Stock Price Down 5.1%Kronos Bio (NASDAQ:KRON) Stock Price Down 5.1%
americanbankingnews.com - May 7 at 12:44 PM
Kronos Bio Announces Participation in Bank of America Securities 2021 Health Care ConferenceKronos Bio Announces Participation in Bank of America Securities 2021 Health Care Conference
finance.yahoo.com - May 6 at 2:29 PM
Kronos Bio, Inc. (NASDAQ:KRON) Sees Large Increase in Short InterestKronos Bio, Inc. (NASDAQ:KRON) Sees Large Increase in Short Interest
americanbankingnews.com - May 4 at 4:44 PM
Kronos Bio (NASDAQ:KRON) Sees Large Volume IncreaseKronos Bio (NASDAQ:KRON) Sees Large Volume Increase
americanbankingnews.com - May 3 at 12:04 PM
Kronos Bio (NASDAQ:KRON) Stock Price Up 5%Kronos Bio (NASDAQ:KRON) Stock Price Up 5%
americanbankingnews.com - April 30 at 1:46 PM
Kronos Bio (NASDAQ:KRON) Shares Gap Up to $23.19Kronos Bio (NASDAQ:KRON) Shares Gap Up to $23.19
americanbankingnews.com - April 27 at 10:52 AM
Heres What Kronos Bio, Inc.s (NASDAQ:KRON) Shareholder Ownership Structure Looks LikeHere's What Kronos Bio, Inc.'s (NASDAQ:KRON) Shareholder Ownership Structure Looks Like
nasdaq.com - April 23 at 11:56 PM
Kronos Bio (NASDAQ:KRON) Stock Price Up 9.2%Kronos Bio (NASDAQ:KRON) Stock Price Up 9.2%
americanbankingnews.com - April 22 at 11:54 AM
Kronos Bio (NASDAQ:KRON) Sees Unusually-High Trading VolumeKronos Bio (NASDAQ:KRON) Sees Unusually-High Trading Volume
americanbankingnews.com - April 21 at 11:40 AM
What Type Of Shareholders Own The Most Number of Kronos Bio, Inc. (NASDAQ:KRON) Shares?What Type Of Shareholders Own The Most Number of Kronos Bio, Inc. (NASDAQ:KRON) Shares?
finance.yahoo.com - April 11 at 1:30 PM
Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained ...Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained ...
apnews.com - April 10 at 11:19 AM
Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained Inhibition of Tumor Growth in Multiple Cancers at AACR Annual Meeting 2021Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained Inhibition of Tumor Growth in Multiple Cancers at AACR Annual Meeting 2021
finance.yahoo.com - April 10 at 11:19 AM
After 21 Years In Private Practice, GC Finds Her 2nd ChapterAfter 21 Years In Private Practice, GC Finds Her '2nd Chapter'
law360.com - April 5 at 5:33 PM
Kronos Bio Appoints Taiyin Yang, Ph.D., to Board of DirectorsKronos Bio Appoints Taiyin Yang, Ph.D., to Board of Directors
finance.yahoo.com - March 26 at 12:39 PM
Kronos Bio Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial ResultsKronos Bio Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 23 at 6:13 PM
Kronos Bio to Present Pre-Clinical Data at the AACR Virtual Annual Meeting 2021 for KB-0742, an ...Kronos Bio to Present Pre-Clinical Data at the AACR Virtual Annual Meeting 2021 for KB-0742, an ...
apnews.com - March 11 at 8:42 AM
Kronos Bio to Present Pre-Clinical Data at the AACR Virtual Annual Meeting 2021 for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified CancersKronos Bio to Present Pre-Clinical Data at the AACR Virtual Annual Meeting 2021 for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers
finance.yahoo.com - March 10 at 7:53 PM
Biopharma GC Appointed To Athira Pharmas BoardBiopharma GC Appointed To Athira Pharma's Board
law360.com - March 8 at 7:38 PM
The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic CompanyThe Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company
msn.com - March 4 at 9:43 AM
DateCompanyBrokerageAction
5/11/2021COMPASS PathwaysCantor FitzgeraldInitiated Coverage
4/1/2021COMPASS PathwaysRoth CapitalInitiated Coverage
10/14/2020COMPASS PathwaysHC WainwrightInitiated Coverage
10/13/2020COMPASS PathwaysEvercore ISIInitiated Coverage
10/13/2020COMPASS PathwaysCanaccord GenuityInitiated Coverage
10/13/2020COMPASS PathwaysCowenInitiated Coverage
10/13/2020COMPASS PathwaysBerenberg BankInitiated Coverage
4/26/2021Repare TherapeuticsMorgan StanleyBoost Price Target
12/29/2020Repare TherapeuticsNorthland SecuritiesReiterated Rating
9/17/2020Repare TherapeuticsBloom BurtonReiterated Rating
7/14/2020Repare TherapeuticsThe Goldman Sachs GroupInitiated Coverage
7/14/2020Repare TherapeuticsPiper SandlerInitiated Coverage
12/18/2020Dynavax TechnologiesWilliam BlairReiterated Rating
5/24/2019Dynavax TechnologiesRoyal Bank of CanadaLower Price Target
12/30/2020Ocular TherapeutixJMP SecuritiesBoost Price Target
11/13/2020Ocular TherapeutixRaymond JamesBoost Price Target
3/17/2020Ocular TherapeutixJefferies Financial GroupInitiated Coverage
11/12/2019Ocular TherapeutixPiper Jaffray CompaniesLower Price Target
(Data available from 5/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.